BioNxt Solutions

Medical solutions from innovation to impact.

[BioNxt Solutions @BioNxtSolutions]

news | financial:
Synlab, XPhyto, Novavax - How long will the Corona boom last?

Read the whole article here:
https://t.co/2X9I6UYIT8

German version:
https://t.co/UzWeezaII7

$XPHY $XPHYF

[BioNxt Solutions @BioNxtSolutions]

XPhyto provides progress update on Psychedelic Medicine Programs and Novel Compounds Milestone

Press release available in English and German here:
https://t.co/Ns5PB8Tgul

$XPHY $XPHYF

[BioNxt Solutions @BioNxtSolutions]

https://t.co/SgBCSeCkJi: XPhyto consistently implements 3-pillar strategy — Market rewards efforts

Read the whole article here:
https://t.co/MKMZQO8RzC

$XPHY $XPHYF

[BioNxt Solutions @BioNxtSolutions]

https://t.co/SgBCSeCkJi: XPhyto Therapeutics - Three hot irons in the fire

Get the whole research here:
https://t.co/pLU66eA6Ra

$XPHY $XPHYF

[BioNxt Solutions @BioNxtSolutions]

XPhyto Reports on its Three Primary Business Divisions

Read the press release here:
https://t.co/zi22hh9TYq

$XPHY $XPHYF

[BioNxt Solutions @BioNxtSolutions]

news | financial:
Novavax, XPhyto Therapeutics, Biontech, Valneva - The vaccine blockbusters are on the move again!

Read the whole article here:
https://t.co/0guGxvO9Q9

$XPHY $XPHYF

[BioNxt Solutions @BioNxtSolutions]

"How XPhyto Therapeutics could revolutionise PCR Testing."

Read the article published by Health Europa in its latest issue of Health Europa Quarterly here:
https://t.co/cvPqMR6VCP

A German translation is available at:
https://t.co/KAN08f6fGe

$XPHY $XPHYF

[BioNxt Solutions @BioNxtSolutions]

XPhyto Executes Covid-ID Lab Sales Contracts with Test Clinics and Pharmacies in Germany as part of Multi-Product Rollout Strategy

Read the press release here:
https://t.co/YaiSwVxDL0

$XPHY $XPHYF

[BioNxt Solutions @BioNxtSolutions]

Tests still in high demand:

@AbbottNews profit and sales beat estimates on vigorous #COVID test demand

https://t.co/kpQMmUNQhR

[BioNxt Solutions @BioNxtSolutions]

XPhyto Provides Update on Integration of 3a-diagnostics GmbH

Read the press release here:
https://t.co/2FwmK5kRKt
$XPHY $XPHYF

[BioNxt Solutions @BioNxtSolutions]

#CBD inhibits #COVID. Science article published last week:
https://t.co/pycveUa319

Inhibition of #SARS-CoV-2 replication is only possible when #THC is absent, so pure CBD is required.

#XPhyto is just ready to go for a first clinical study with Vektor's CBD-ODF.

$XPHY $XPHYF

[BioNxt Solutions @BioNxtSolutions]

"Fast PCR tests: Are they the solution?"

The Stuttgarter Zeitung presents under this headline rapid on-site #PCR tests as a possible solution for the emerging test shortage.

Read the article online (German, paid):
https://t.co/VFsGwmJ8UL

$XPHY $XPHYF

[BioNxt Solutions @BioNxtSolutions]

XPhyto Announces Head of Sales, Europe

Mr. Zdarek will focus on building out #distribution, #sales and #marketing, with high priority on the commercialization of Covid-ID Lab, the Company’s rapid RT-#PCR test.

Read the press release here:
https://t.co/MBEZgxIHmz
$XPHY $XPHYF

[BioNxt Solutions @BioNxtSolutions]

XPhyto signs Distribution Agreement for Czech Republic, rollout planned for Hungary, Slovakia, Ukraine and Russia

Read the press release here:
https://t.co/FGf26UYfn7

$XPHY $XPHYF

[BioNxt Solutions @BioNxtSolutions]

XPhyto Announces New Director of Business Development and Head of Diagnostic Research

Mr. Roland Spleiss joined as the Director of Business Development
Dr. Heinrich Jehle joined as Head of Diagnostic Research.

Read the press release here:
https://t.co/VsPOffvRY0
$XPHY $XPHYF

[BioNxt Solutions @BioNxtSolutions]

XPhyto #Epilepsy #clinicaltrial planned in 2022 with its proprietary fast-dissolving CBD oral strips

European human CBD bioavailability study will commence in January 2022.

https://t.co/wQCDRZAIzA
$XPHY $XPHYF

[BioNxt Solutions @BioNxtSolutions]

XPhyto Completes Strategic #Acquisition of 3a-diagnostics

- Positioned as leading #Biosensor producer
- Adds IP and scientific expertise
- Gains technical and business synergies
- Secures #infectious #disease biosensor portfolio

https://t.co/WTIA0qunHH

$XPHY $XPHYF

[BioNxt Solutions @BioNxtSolutions]

We’re leading ground-breaking work in pharmaceuticals.

From applying psychedelics to major neurological diseases to developing rapid testing to support pandemic management; our work is all about innovation to impact.

Learn more about us here: https://t.co/QVJ16TABqR

$XPHY

[BioNxt Solutions @BioNxtSolutions]

XPhyto Therapeutics Closes Private Placements for Gross Proceeds of $7,000,0000

$XPHY $XPHYF

[BioNxt Solutions @BioNxtSolutions]

As more people start to see the potential of psychedelics as a treatment for severe mental health concerns, investment in the innovative companies at the forefront continues to surge.

Read the full @EPM_Magazine article here: https://t.co/vI98zX3j9d

$XPHY